Biomarker testing remains a cornerstone of precision oncology, particularly for non–small cell lung cancer, yet obstacles ...

Biomarker profiles are tumor-specific and can predict sensitivity or resistance to targeted therapy or immune checkpoint inhibition, enabling more individualized treatment selection than histology ...

Please provide your email address to receive an email when new articles are posted on . Time from biopsy to receipt of molecular testing results decreased, but most of the improvement occurred at the ...

Precision medicine relies on biomarker testing to match therapies to specific cancers, yet many patients remain untested due to standardization issues. Recommendations include educating clinicians, ...

BeiGene is back with a new partnership and oncology campaign to raise awareness about biomarker testing for patients with chronic lymphocytic leukemia (CLL), a blood cancer marked by the ...

Young lung cancer patients have a higher incidence of targetable biomarkers, necessitating comprehensive testing for ALK fusions and EGFR mutations. Repeat biomarker testing is essential when ...

Although treatment of advanced gastroesophageal cancer is increasingly dependent on biomarkers, only about 40% of patients are tested. For patients to fully benefit from the latest targeted therapies, ...

We tried out one of the most advanced baseline diagnostic panels available – here’s what we discovered about our health with this biomarker testing… Preventative healthcare has long been the preserve ...

A new generation of blood tests is making it easier for doctors to look for biological signs of Alzheimer’s disease, ...

The U.S. Biomarker Testing Market is estimated to be worth USD 11.67 billion in 2025 and is projected to increase at a compound annual growth rate (CAGR) of 2.25% from 2026 to 2035, reaching USD 14.57 ...

Advanced multi-omics data analysis and biostatistical expertise to sharpen target and biomarker decisions across the platformPRINCETON, N.J., and ...

Biomarker testing helps doctors create personalized cancer treatments with fewer side effects. Many health insurers deny coverage for this testing, calling it "experimental." Lack of insurance ...